Route 92 Medical Clears FDA for FreeClimb 46

FDA cleared Route 92 Medical's FreeClimb 46 catheter on 28 September 2026, the company said, the newest and smallest-diameter addition to a neurovascular access platform used alongside its Tenzing 4 delivery catheter. The 510(k) clearance extends a product family that already spans the FreeClimb 54, 70 and 88, pushing the line's reach toward smaller, more distal vessels.

What was cleared

The clearance covers the FreeClimb 46 catheter used as an integrated system with Route 92's existing Tenzing 4 delivery catheter for neurovascular access — the pathway interventionalists use to reach the brain's blood vessels for stroke thrombectomy and related procedures. Route 92 describes Tenzing's navigational design as enabling atraumatic, precise and controlled access through neurovascular anatomy, and positions FreeClimb 46 specifically as reaching smaller and more distal vessels than the rest of the FreeClimb line. Regulatory News was not able to locate the verbatim FDA indications-for-use language from a 510(k) summary in the material available; the description above reflects how the company itself characterizes the clearance, not a direct quotation of FDA's regulatory text.

Where it fits in the platform

FreeClimb 46 is not a first product: it joins the FreeClimb 54, 70 and 88 catheters Route 92 has cleared in prior rounds, each denser numbering apparently tracking catheter diameter as the line has extended toward smaller vessels over successive clearances. That kind of sequential 510(k) expansion — a base platform, then progressively smaller or more specialized variants — is a common regulatory strategy in neurovascular access devices, where incremental design changes can often rely on predicate devices already in the company's own cleared portfolio rather than requiring a wholly new review pathway each time.

The clinical backdrop, without overclaiming it

Smaller, more trackable neurovascular catheters matter because a substantial share of acute ischemic strokes originate in distal or medium-sized vessels that older, larger-bore catheters struggle to reach cleanly — independent clinical literature puts that share at roughly a quarter to two-fifths of acute ischemic strokes, and distal medium vessel occlusion (DMVO) treatment is an active area of stroke-device development industry-wide. No source Regulatory News reviewed, including Route 92's own materials, explicitly ties FreeClimb 46 or Tenzing 4 to a DMVO indication or to any specific trial data. That clinical context explains why the device category matters, not what this particular clearance was studied or indicated for.

Frequently asked questions

What did FDA clear on 28 September 2026?

A 510(k) premarket notification for Route 92 Medical's FreeClimb 46 catheter, used together with the company's Tenzing 4 delivery catheter, for neurovascular access. It is the newest, smallest-diameter member of the FreeClimb family, which already includes the FreeClimb 54, 70 and 88.

What is the FreeClimb 46 for?

Route 92 describes it as extending the FreeClimb platform's reach to smaller and more distal vessels, with Tenzing 4 providing what the company calls atraumatic, precise and controlled navigation through neurovascular anatomy. Regulatory News could not locate the verbatim FDA indications-for-use text from the 510(k) summary; the description here reflects the company's own characterization.

Is this tied to a specific stroke indication, like distal vessel occlusion?

No source Regulatory News reviewed ties FreeClimb 46/Tenzing 4 to a specific indication such as distal medium vessel occlusion (DMVO) stroke. Smaller, more trackable neurovascular catheters are a general area of device development relevant to DMVO, which independent clinical literature estimates accounts for roughly a quarter to two-fifths of acute ischemic strokes — but that is market and clinical context, not a claim about this product's indication.

Is this Route 92's first clearance?

No. The FreeClimb line already includes the 54, 70 and 88 catheters, cleared in earlier rounds, and the company said in July 2026 it had reached 200 issued patents across its neurovascular portfolio — a company-reported figure republished across several outlets.